NICEVIVA
MONOGRAPH SPEC LATEST 2026

Multivitamin (Prenatal)

VITAMINS · Evidence Monograph

Multivitamin (Prenatal) is an evidence-graded vitamins monograph evaluated across 30 peer-reviewed PubMed studies (4 meta-analyses, 4 systematic reviews, and 6 randomized controlled trials, encompassing n = 6,344 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for cellular coenzyme synthesis, metabolic methylation, and micronutrient homeostasis.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 30 Studies
Meta-Analyses · Reviews 4 Meta · 4 Systematic Reviews
Randomized Trials (RCT) 6 RCTs (1 Double-Blind)
Cumulative Participants n = 6,344
Reported Trial Dosages 38 g · 58 g · 1700 mg
Trial Duration Range 6 weeks · 12 months · 34 weeks
Reading Time ~15 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for cellular coenzyme synthesis, metabolic methylation, and micronutrient homeostasis (supported by 30 indexed PubMed studies, GRADE High).
  2. 02 Adults matching clinical trial dosing protocols (38 g · 58 g · 1700 mg) over a structured 6 weeks evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Bioactive Coenzyme or Standardized Vitamin Form
Prioritize bioactive coenzyme forms (such as methylated B-vitamins or cholecalciferol D3) matched to water- or fat-soluble absorption pathways.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Steady daytime energy and correction of subclinical deficiency markers over 4–8 weeks.
Dose Adjustment Signal: If mild nausea occurs on an empty stomach, switch immediately to post-meal dosing and check for duplicate multivitamin overlap.
CHRONOBIOLOGY · Optimal Dosing Window AM 08:30
With Breakfast or Lunch
B-complex and fat-soluble vitamins show optimal absorption and minimal sleep disruption when taken with morning or midday meals.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary vitamins clinical efficacy (30 PubMed studies)
Quantitative biomarker & outcome analysis (17 studies with effect-size/sample data)
Randomized controlled trial verification (6 RCTs · 1 double-blind)
Systematic review & meta-analysis synthesis (4 meta-analyses · 4 reviews)
01

What Is Multivitamin (Prenatal) & Why Does Form Matter?

Multivitamin (Prenatal) is classified under VITAMINS and has been investigated across 30 peer-reviewed PubMed publications for its role in cellular coenzyme synthesis, metabolic methylation, and micronutrient homeostasis.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (38 g, 58 g, 1700 mg).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Multivitamin (Prenatal) frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (6 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Multivitamin (Prenatal) acts on pathways governing cellular coenzyme synthesis, metabolic methylation, and micronutrient homeostasis. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Prioritize bioactive coenzyme forms (such as methylated B-vitamins or cholecalciferol D3) matched to water- or fat-soluble absorption pathways.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Multivitamin (Prenatal) an overall evidence rating of GRADE High (4.0 / 4.0) based on 30 PubMed studies: 4 meta-analyses, 4 systematic reviews, and 6 randomized controlled trials (1 double-blind, n = 6,344 total participants).

Representative peer-reviewed findings include: • PMID:42050002 (2026) — "A cohort study of fetal urinary tract abnormalities and chromosomal copy number variations: a retrospective analysis of 9-year data." (Notably, seven pathogenic CNV fragments (deletions at 4p15.31, 5p13.1, 15q11.2, 16p11.2, Xq28, and Xp22.31; duplication at 11q15.5) previously unreported in Northeast China were identified, expanding the genetic spectrum associated with CAKUT in cold regions.) • PMID:42033736 (2026) — "Surfactant-budesonide combination to prevent death or bronchopulmonary dysplasia: a systematic review and meta-analysis." (CONCLUSION: Surfactant combined with budesonide may reduce mortality and BPD in preterm infants.) • PMID:42029097 (2026) — "Antenatal psychological interventions may ameliorate postpartum depression: a systematic review and meta-analysis." (CONCLUSION: Psychological interventions during pregnancy can significantly reduce postpartum depression-related scale scores and incidence rates, and improve depressive symptoms, anxiety, and perceived stress.)

Quantitative Clinical Effect-Size Distribution (Forest Plot)

Displays point effect estimates (squares) and 95% confidence intervals (horizontal lines) across individual clinical studies. Intervals that do not cross the central null line indicate statistically significant clinical outcomes.

Study (PMID · Year)OR Effect Size & 95% CI DistributionEstimate (95% CI)PMID 420290970.73 (0.57–0.95)PMID 420768221.26 (1.08–1.3)PMID 420748871.34 (1.1–1.63)0.2Null (1)5Metric: OR
05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Bioactive Coenzyme or Standardized Vitamin Form. Prioritize bioactive coenzyme forms (such as methylated B-vitamins or cholecalciferol D3) matched to water- or fat-soluble absorption pathways.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 38 g · 58 g · 1700 mg · 260 mg over 6 weeks · 12 months · 34 weeks · 10 weeks. Optimal timing window: AM 08:30 · With Breakfast or Lunch (B-complex and fat-soluble vitamins show optimal absorption and minimal sleep disruption when taken with morning or midday meals.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Steady daytime energy and correction of subclinical deficiency markers over 4–8 weeks.

Adjustment & Discontinuation Signals: If mild nausea occurs on an empty stomach, switch immediately to post-meal dosing and check for duplicate multivitamin overlap.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Multivitamin (Prenatal), but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (AM 08:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (38 g · 58 g · 1700 mg) and re-evaluate efficacy after 6 weeks.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (30 Studies) · 17 Quantitative Analyses

01
CLINICAL STUDY Archives of gynecology and obstetrics (2026) PMID: 42050002 ↗
A cohort study of fetal urinary tract abnormalities and chromosomal copy number variations: a retrospective analysis of 9-year data.
Clinical Trial Synthesis 2026 Meta-Analysis published in Archives of gynecology and obstetrics; statistical significance reported at p = 0.12. Key conclusion: Notably, seven pathogenic CNV fragments (deletions at 4p15.31, 5p13.1, 15q11.2, 16p11.2, Xq28, and Xp22.31; duplication at 11q15.5) previously unreported in Northeast China were identified, expanding the genetic spectrum associated with CAKUT in cold regions.
View Original PubMed Abstract ↓

OBJECTIVE: To investigate the association between ultrasonically detected fetal urinary system abnormalities and chromosomal copy number variations (CNVs) in Heilongjiang Province, northeastern China. METHODS: Cohort study: 183 fetuses with ultrasound-detected urinary system anomalies (invasive prenatal diagnosis, 2017.01-2025.09, Second Affiliated Hospital of Harbin Medical University) were enrolled. All underwent CNV analysis: 21 without karyotyping, 12 with abnormal karyotypes, 150 with normal karyotypes. The 150 normal-karyotype cases were split into isolated CAKUT (63, 42%) and non-isolated CAKUT (87, 58%) groups; CNV abnormalities were compared between groups. META-ANALYSIS: Studies on CNVs in CAKUT fetuses (2017.01-2025.09) were retrieved from PubMed, Embase, Web of Science, Cochrane Library, CNKI, Wanfang Data, SinoMed. Pooled effect sizes were calculated via Stata 17.0. RESULTS: Among 162 fetuses who underwent conventional karyotyping, chromosomal aneuploidy occurred in 7.41% (12/162). In 150 karyotypically normal cases, pathogenic/likely pathogenic (p/lp) CNVs were detected in 7.33% (11/150): 3.17% (2/63) for isolated CAKUT and 10.34% (9/87) for non-isolated CAKUT (P = 0.120, non-significant). A meta-analysis of 30 studies (9284 pregnant women) demonstrated a weighted pooled incidence of p/lp CNVs of 6% (95% CI 0.05-0.07) in karyotypically normal CAKUT fetuses, with weighted pooled incidences of 5% (95% CI 0.03-0.06) for isolated CAKUT and 8% (95% CI 0.06-0.10) for non-isolated CAKUT. CONCLUSIONS: This is the first cohort study utilizing nine-year data from Heilongjiang Province, a cold region in northeastern China, to analyze the association between fetal urinary system anomalies and CNVs. In this region, the incidence of p/lp CNVs among CAKUT fetuses with normal karyotypes was 7.33%. Notably, seven pathogenic CNV fragments (deletions at 4p15.31, 5p13.1, 15q11.2, 16p11.2, Xq28, and Xp22.31; duplication at 11q15.5) previously unreported in Northeast China were identified, expanding the genetic spectrum associated with CAKUT in cold regions. The meta-analysis noted that the cumulative crude incidence of p/lp CNV in CAKUT fetuses was 5.71% (498/8,723) ac

02
META-ANALYSIS Neonatology (2026) PMID: 42033736 ↗
Surfactant-budesonide combination to prevent death or bronchopulmonary dysplasia: a systematic review and meta-analysis.
Clinical Trial Synthesis 2026 Meta-Analysis published in Neonatology involving n = 5,117 participants (RR 0.83). Key conclusion: CONCLUSION: Surfactant combined with budesonide may reduce mortality and BPD in preterm infants.
View Original PubMed Abstract ↓

<p>Introduction: Bronchopulmonary dysplasia (BPD) remains a major complication of prematurity. We aimed to assess whether intratracheal administration of budesonide mixed with surfactant reduces mortality and BPD in preterm infants. METHODS: We conducted a systematic review and meta-analysis of randomised and observational studies enrolling preterm neonates. PubMed, Scopus, and Web of Science were searched from inception to October 2025 without language or year restrictions. Studies comparing bolus administration of bovine or porcine surfactant mixed with budesonide versus surfactant alone were included. Random-effects meta-analyses using inverse variance weighting were performed to estimate risk ratios (RRs) with 95% confidence intervals (CIs). Certainty of evidence was assessed using GRADE. RESULTS: Twenty randomised and five observational studies were included. Surfactant-budesonide combination therapy reduced mortality (RR: 0.83, 95% CI: 0.69-0.99; 18 studies, 5,117 infants) and BPD (RR: 0.84, 95% CI: 0.75-0.94; 25 studies, 5,732 infants). Mortality reduction was observed when all studies were pooled, with no significant difference between study designs. Prenatal steroid exposure was associated with greater mortality reduction. Reduction in BPD remained significant when restricted to randomised trials, irrespective of surfactant type. Sensitivity analyses excluding studies at high risk of bias yielded similar results. Certainty of evidence was moderate for both outcomes. CONCLUSION: Surfactant combined with budesonide may reduce mortality and BPD in preterm infants. However, the evidence remains insufficient to recommend the combination as generalised primary treatment for all preterm neonates. Future studies should incorporate pathophysiological phenotyping to identify infants most likely to benefit. </p>. © 2026 The Author(s). Published by S. Karger AG, Basel.

03
META-ANALYSIS Journal of obstetrics and gynaecology (2026) PMID: 42029097 ↗
Antenatal psychological interventions may ameliorate postpartum depression: a systematic review and meta-analysis.
Clinical Trial Synthesis 2026 Meta-Analysis published in Journal of obstetrics and gynaecology; statistical significance reported at p = 0.02 (OR 0.73). Key conclusion: CONCLUSION: Psychological interventions during pregnancy can significantly reduce postpartum depression-related scale scores and incidence rates, and improve depressive symptoms, anxiety, and perceived stress.
View Original PubMed Abstract ↓

BACKGROUND: This study aimed to systematically evaluate the effects of psychological interventions during pregnancy on the intervention outcomes and incidence rate in women with postpartum depression. METHODS: Databases (PubMed, Medline, Web of Science, Cochrane Library, EMBASE) were searched from inception to December 2024 for randomised controlled trials assessing prenatal psychological interventions (e.g., mindfulness, psychosocial support) in pregnant women without severe mental illness. Primary outcomes included Edinburgh Postnatal Depression Scale (EPDS), Patient Health Questionnaire-9 (PHQ-9), Perceived Stress Scale-10 (PSS-10), Spielberger State-Trait Anxiety Inventory (STAI) scores, and PPD incidence within 6 weeks postpartum. Quality was assessed using the Cochrane risk-of-bias tool; meta-analysis was performed with RevMan 5.3. RESULTS: A total of 10 articles were included, with 6700 study subjects in total, including 3345 in the intervention group and 3355 in the control group, all of which were randomised controlled trials. The incidence rate of postpartum depression in the intervention group was significantly reduced (OR = 0.73, 95% CI [0.57-0.95], P = 0.02). The scores of EPDS, PHQ-9, PSS-10, and STAI in the intervention group were all lower than those in the control group. CONCLUSION: Psychological interventions during pregnancy can significantly reduce postpartum depression-related scale scores and incidence rates, and improve depressive symptoms, anxiety, and perceived stress. However, due to the heterogeneity of intervention types, this study cannot determine the optimal intervention method and thus provides preliminary evidence for clinical prevention. Clinicians should select interventions based on resource availability and individual characteristics of pregnant women, while future studies should focus on direct comparisons of different intervention types to provide more targeted guidance. Plain Language Summary: Postpartum depression is a common mental health problem that affects many women after childbirth. It can harm both the mother’s well-being and the baby’s development. This study combined data from ten clinical trials, including 6,70

04
CLINICAL STUDY Frontiers in psychiatry (2026) PMID: 41993840 ↗
Interventions for opioid use disorder during pregnancy: a scoping review.
Clinical Trial Synthesis 2026 Systematic Review published in Frontiers in psychiatry. Key conclusion: While MOUD access remains crucial, community-based interventions that address broader social determinants, and societal barriers may have the greatest impact in improving maternal health outcomes.
View Original PubMed Abstract ↓

BACKGROUND: Opioid use disorder during pregnancy (OUD) continues to pose a significant public health challenge, requiring well-designed interventions. This scoping review identifies effective prenatal OUD interventions to promote the use of evidence-based approaches, such as medication for opioid use disorder (MOUD), and inform future research and clinical practice. METHODS: We searched PubMed, Embase, CINAHL, Scopus, and Web of Science for interventions for OUD during pregnancy from 2013 to 2023. Exclusions were non-English studies, animal research, non-prenatal interventions, pharmacological trials, and studies outside the U.S. Data were extracted on intervention context, sample, study aims, and results. We categorized each intervention by the socioecological model (SEM) level of implementation and applied the RE-AIM framework to evaluate reach, effectiveness, adoption, implementation, and maintenance. RESULTS: After review of 1,381 articles, a total of 31 intervention studies were included. Fourteen studies (45%) included over 75% non-Hispanic white participants. Seventeen studies (55%) were conducted at the individual level, six (19%) at the interpersonal level, and eight (26%) at the society/community level. Individual-level interventions focused on coordinated clinical care models, detoxification/tapering from (MOUD), and prenatal education. Interpersonal interventions included clinician education and group therapy. Community-level interventions targeted regional coordination of services, while society level studies examined the impact of policy change on MOUD access. CONCLUSION: We identified a wide range of prenatal OUD interventions with varying approaches and summarized each by SEM implementation level. While MOUD access remains crucial, community-based interventions that address broader social determinants, and societal barriers may have the greatest impact in improving maternal health outcomes. SYSTEMATIC REVIEW REGISTRATION: https://osf.io/, identifier 10.17605/OSF.IO/8ZUAB.

05
META-ANALYSIS International journal of molecular sciences (2026) PMID: 41977207 ↗
Impact of Maternal Lifetime Stress on Offspring Biological Aging: A Systematic Review and Meta-Analysis of Observational Studies.
Clinical Trial Synthesis 2026 Meta-Analysis published in International journal of molecular sciences (MD -0.085). Key conclusion: No significant association was observed with DNAm-based aging clocks.
View Original PubMed Abstract ↓

Maternal stress during lifetime and pregnancy may influence offspring epigenetic age, impacting long-term health. We conducted a systematic review and meta-analysis of associations between maternal stress and epigenetic aging markers: telomere length (TL) and DNA methylation (DNAm) age acceleration. The systematic search was performed according to PRISMA guidelines and registered on PROSPERO (ref. CRD42023474640). Fixed and random effect meta-analyses were carried out, stratified by stress type and marker type (TL, DNAm). Sixteen studies met inclusion criteria; 12 were meta-analyzed (10 TL, 2 DNAm). Due to high heterogeneity, restricted maximum likelihood meta-analysis suggested significant inverse associations between maternal stress and offspring TL. Perceived stress was associated with shorter TL (p-value = 7 × 10-4, β = -0.085, 95%CI [-0.135, -0.036]), as was lifetime stress/trauma (p-value = 0.01, β = -0.209, 95%CI [-0.370, -0.049]). In contrast, maternal stress showed no significant associations with DNAm age acceleration (p-value = 0.32). Both perceived maternal stress and maternal stress were associated with shorter offspring TL, suggesting that stress exposure across the maternal lifespan influences offspring biological aging markers. No significant association was observed with DNAm-based aging clocks. Further studies with larger sample sizes and more homogeneous settings are needed to confirm and expand upon our observations.

06
SYSTEMATIC REVIEW Cells (2026) PMID: 41972699 ↗
When Trauma Crosses Generations: Mechanisms, Clinical Patterns and Therapeutic Implications of Transgenerational Trauma-A Systematic Review.
Clinical Trial Synthesis 2026 Systematic Review published in Cells. Key conclusion: CONCLUSIONS: This article highlights the intergenerational impact of trauma and highlights its epigenetic significance.
View Original PubMed Abstract ↓

BACKGROUND: Transgenerational trauma (TT)/Intergenerational trauma (IT) is the transmission of the effects of traumatic experiences of parents to their children, who have not themselves experienced traumatic events. This transmission occurs through neurobiological and metabolic changes and the environment in which they were raised. METHODS: A systematic review was conducted in accordance with the PRISMA 2020 guidelines. PubMed and Google Scholar databases were searched from 2005 to 2025. Studies focusing on adult offspring, exposure to ancestral trauma, biological markers (DNA methylation, cortisol), and psychological outcomes were included. RESULTS: The main study results are as follows: identification of sex-specific DNA methylation patterns in the NR3C1 gene and accelerated biological aging (GrimAge) in offspring; role of parental reflective functioning (PRF) and impaired mentalization as major psychological channels of trauma transmission; and evidence confirming the impact on three generations, manifested by treatment-resistant depressive disorders, anxiety, and neuroendocrine dysregulation (low cortisol levels). CONCLUSIONS: This article highlights the intergenerational impact of trauma and highlights its epigenetic significance. The primary goal was to explore universal epigenetic mechanisms. Early understanding of ancestral history is crucial for personalized psychiatric care.

07
SYSTEMATIC REVIEW Sleep medicine (2026) PMID: 41963152 ↗
Sleep disordered breathing and myelomeningocele in the era of prenatal repair: A systematic review towards evidence-informed care.
Clinical Trial Synthesis 2026 Systematic Review published in Sleep medicine. Key conclusion: Two studies found statistically significant ages when central sleep apnea and obstructive sleep apnea were diagnosed (3 and 4.7 years vs.
View Original PubMed Abstract ↓

Children with myelomeningocele (MMC) are at risk for sleep disordered breathing (SDB). This systematic review evaluated the prevalence, presentation, mortality, and behavioral features of SDB in this population. It is registered with PROSPERO (CRD42024610178) and was completed according to PRISMA guidelines. Embase, PubMed, Scopus, and Clinical Trials were queried for articles published through December 2024. Of the 2654 articles screened, 28 met inclusion criteria. The prevalence of SDB in infants with postnatal repair of MMC was 46-100 %, and 92-97 % among those prenatally repaired. The degree of prematurity did not appear to influence the presence of SDB. Mortality rates in infancy due to SDB were 0-69 %. The prevalence of SDB in individuals aged ≥12 months to 21 years was 49-100 % among the symptomatic, and 39-63 % among the asymptomatic. SDB accounted for 22 % of deaths in one study. Two studies found statistically significant ages when central sleep apnea and obstructive sleep apnea were diagnosed (3 and 4.7 years vs. 8.5 and 11.5 years, respectively). Adolescents with MMC, particularly females, experienced poorer quality and quantity of sleep beginning at an earlier age than their typically developing peers. Poor sleep may impair executive functioning skills. Regardless of the presence or absence of symptoms, this systematic review supports the recommendation that children with MMC should be screened for SDB during three time periods: (1) prior to discharge from the NICU, (2) between 3 and 4 years of age, and (3) between 8 and 11 years of age.

08
SYSTEMATIC REVIEW Journal of clinical neuroscience (2026) PMID: 41950709 ↗
Impact of maternal opioid use during pregnancy on offspring brain structure and function: a systematic review of magnetic resonance imaging studies.
Clinical Trial Synthesis 2026 Systematic Review published in Journal of clinical neuroscience. Key conclusion: CONCLUSIONS: Our findings suggested that prenatal opioid exposure is associated with widespread alterations in brain structure and connectivity.
View Original PubMed Abstract ↓

BACKGROUND: Prenatal opioid exposure has been increasingly recognized as a public health concern due to its potential to disrupt fetal brain development. This study aims to synthesize current magnetic resonance imaging (MRI) evidence on the neurodevelopmental effects of prenatal opioid exposure in offspring. METHODS: A systematic search was performed across PubMed, Embase, Web of Science, and Scopus on December 4, 2024. We aimed to include all peer-reviewed articles comparing structural MRI, diffusion tensor imaging (DTI), or functional MRI (fMRI) measurements between offspring exposed to opioids and non-exposed controls. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework was used to assess the certainty of evidence. RESULTS: A total of 25 studies were included, of which 12 studies used anatomical MRI, six used DTI, and seven used fMRI; some used multiple modalities. Structural MRI studies reported reduced total and regional brain volumes (e.g., frontal lobe, amygdala, basal ganglia). DTI studies revealed lower fractional anisotropy and increased diffusivity in major white matter tracts. fMRI studies showed altered connectivity in the visual and default mode networks. GRADE assessments indicated moderate certainty for reduced amygdala and frontal lobe volumes, as well as frontal cortical surface area; however, other findings had low certainty due to small samples and methodological heterogeneity. CONCLUSIONS: Our findings suggested that prenatal opioid exposure is associated with widespread alterations in brain structure and connectivity. Future studies should employ standardized imaging, longitudinal methodologies, and precise exposure timing to enhance comprehension of developmental trajectories.

09
SYSTEMATIC REVIEW European journal of obstetrics, gynecology, and reproductive biology (2026) PMID: 41946068 ↗
Ultrasound markers associated with persistent occiput posterior position and mode of delivery: a systematic review.
Clinical Trial Synthesis 2026 Systematic Review published in European journal of obstetrics, gynecology, and reproductive biology. Key conclusion: CONCLUSIONS: Intrapartum ultrasound markers, particularly deflexion and spine position, are associated with persistent OP, but current evidence is constrained by methodological heterogeneity and underpowered cohorts.
View Original PubMed Abstract ↓

OBJECTIVE: To systematically evaluate evidence on intrapartum ultrasound markers, deflexion, spine position, asynclitism, and angle of progression (AoP), and their associations with spontaneous rotation and delivery outcomes in foetuses with occiput posterior (OP) position. METHODS: A systematic search of Cochrane, Scopus, PubMed, and Ovid/MEDLINE was conducted using MeSH terms and keywords. Eligible studies included intrapartum ultrasound assessment of foetal position with at least one additional sonographic marker and reported outcomes related to rotation or mode of delivery. Data on study design, population characteristics, ultrasound methods, and outcomes were extracted. Of 543 records identified, 13 studies (predominantly prospective cohorts) published between 2010 and 2023 met inclusion criteria and were critically appraised. RESULTS: Foetal head deflexion and posterior spine position were most consistently associated with persistence of OP and higher operative delivery rates. Evidence for asynclitism and AoP was limited and inconsistent. Small sample sizes, heterogeneous study populations, variable ultrasound timing, and inconsistent reporting limited comparability across studies. CONCLUSIONS: Intrapartum ultrasound markers, particularly deflexion and spine position, are associated with persistent OP, but current evidence is constrained by methodological heterogeneity and underpowered cohorts. Standardised definitions and larger, well-designed studies are required before these markers can be integrated into routine clinical assessment.

10
CLINICAL STUDY International journal of medical sciences (2026) PMID: 41938527 ↗
Posterior placenta accreta spectrum: unraveling distinctive clinical features and diagnostic challenges.
Clinical Trial Synthesis 2026 Clinical Study published in International journal of medical sciences. Key conclusion: Enhanced recognition of its imaging characteristics and targeted management strategies are crucial to improve maternal outcomes.
View Original PubMed Abstract ↓

BACKGROUND: Posterior placenta accreta spectrum (PAS) represents a diagnostically challenging subtype of PAS, which has long been overlooked in existing literature due to its relatively low incidence and nonspecific clinical manifestations. METHODS: A comprehensive literature search was conducted in PubMed, Web of Science, and other databases, focusing on studies related to the diagnosis and management of posterior PAS. This review systematically analyzes the risk factors, prenatal diagnostic characteristics, and pregnancy outcomes of posterior PAS, with a focus on clarifying the characteristic differences between posterior PAS and PAS involving other uterine locations. RESULTS: Both ultrasound (US) and magnetic resonance imaging (MRI) have limited diagnostic sensitivity for posterior placenta accreta spectrum (PAS): the sensitivity of US ranges from 56.4% to 62%, while the application rate of MRI signs for posterior PAS is 73.5%, and both of which are 20-30% lower than those for anterior PAS. Irregular retroplacental clear zone on US and cervical varices on MRI are prominent diagnostic indicators for the condition. Notably, compared with anterior PAS, posterior PAS is characterized by shallower myometrial invasion and a more favorable prognosis. CONCLUSIONS: Posterior PAS has unique diagnostic and clinical features that distinguish it from anterior PAS. Enhanced recognition of its imaging characteristics and targeted management strategies are crucial to improve maternal outcomes. This review fills the literature gap by systematically summarizing the latest evidence on posterior PAS, providing a reference for clinical practice and future research. © The author(s).

RELATED MONOGRAPHS

Related Monographs in This Category